Business Context and Reporting Period
This Form 8-K was filed by Renovaro Biosciences Inc. (formerly Enochian Biosciences Inc.) on August 7, 2023, reporting events occurring on August 1, 2023. The company is a Delaware corporation with its principal executive offices in Los Angeles, California. The filing details a private placement of equity securities and the amendment and conversion of a previously issued promissory note.
Key Financial Metrics and Capital Structure
- Private Placement Proceeds: The company raised $2,000,000 in cash from the sale of 280,005 Units at a price of $7.13 per Unit.
- Debt Conversion: An additional $2,000,000 of outstanding principal from a Promissory Note was converted into 280,005 Units.
- Remaining Debt: A principal balance of $3,000,000 remains outstanding under the Promissory Note following the conversion.
- Equity Issued: The transaction resulted in the issuance of 561,010 shares of Series A Convertible Preferred Stock and warrants to purchase 2,805,050 shares of Common Stock.
- Warrant Terms: Warrants have an exercise price of $0.65 per share and are exercisable for five years.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods. The material change reported is the significant reduction of debt obligations through the conversion of $2,000,000 of the Promissory Note into equity, alongside the infusion of $2,000,000 in new cash capital. Additionally, the company established a new class of Series A Convertible Preferred Stock with specific liquidation preferences and voting rights.
Guidance, Outlook, and Material Agreements
- Use of Proceeds: Net proceeds from the private placement are intended for general corporate purposes.
- Preferred Stock Rights:
- Conversion: Preferred Stock converts to Common Stock at a 1:10 ratio.
- Liquidation Preference: Holders are entitled to $7.13 per share before any distribution to Common Stockholders.
- Voting: Preferred Stockholders vote on an as-converted basis alongside Common Stockholders.
- Risks and Contingencies: The filing notes that the securities were sold pursuant to Regulation S to non-U.S. persons. No underwriters were engaged, and no general solicitation was conducted.
Investor Verification Checklist
- Verify the total outstanding debt balance of $3,000,000 remaining on the Promissory Note and its maturity terms.
- Confirm the dilution impact of the 5,610,100 shares of Common Stock issuable upon conversion of Preferred Stock and the 2,805,050 shares issuable upon exercise of Warrants.
- Review the "Qualified Merger" definition in the Certificate of Designation (Exhibit 3.1) to understand automatic conversion triggers.
- Assess the company's cash runway given the $2,000,000 cash infusion and the stated use for "general corporate purposes."